← Human Trials & Peer-Reviewed Studies
Effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide
Plain-language guide to PMID 20671294 (2011): randomized controlled trial study of Liraglutide.
Key Facts
- PMID
- 20671294
- Journal
- Journal of clinical pharmacology
- Year
- 2011
- Study type
- Randomized Controlled Trial
- Authors
- Kapitza C et al. (6 authors)
- DOI
- 10.1177/0091270010374474
- Registered trial
- NCT01513525
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Liraglutide.
PubMed holds no abstract for it, so this summary is built from its title ("Effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide") and its index terms.
Who Took Part
By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.
How the Study Was Run
In design terms this was a randomized study.
The participants were allocated by chance, so the Liraglutide group and the comparison group should start out alike.
What Was Measured
PubMed files the paper under topics including Area Under Curve, Glucagon-Like Peptide 1, Hypoglycemic Agents and Liraglutide.
What This Means in Plain Language
The paper is a randomized study of Liraglutide.
The publication is from 2011 (Journal of clinical pharmacology), a journal based in England.
More context: the Liraglutide compound page, all human trials.
Our Notes on the Compound
Liraglutide: A once-daily GLP-1 receptor agonist peptide; sold as Victoza for type 2 diabetes and Saxenda for weight management.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.